Healio
Healio

Association for Research in Vision and Ophthalmology
ByAndrew A. Moshfeghi, MD, MBA
ByKate Young
Fact checked byChristine Klimanskis, ELS

Read more

June 10, 2023
2 min watch
Save

VIDEO: Axitinib intravitreal implant promising in AMD treatment in phase 1 trial

ByAndrew A. Moshfeghi, MD, MBA
ByKate Young
Fact checked byChristine Klimanskis, ELS

Key takeaways:

  • Eighty percent of patients could go 6 months without an additional aflibercept injection.
  • Seventy-three percent of patients could go up to 10 months without additional aflibercept.

NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Andrew A. Moshfeghi, MD, MBA, discusses an interim analysis of a phase 1 clinical trial evaluating OTX-TKI for neovascular age-related macular degeneration.

“What we found was that 80% of patients could go 6 months without requiring an additional aflibercept injection, and 73% of patients could go as long as 10 months,” Moshfeghi said.

Sources/Disclosures

Collapse
Source:

Moshfeghi AA, et al. U.S. phase 1 study of intravitreal axitinib implant (OTX-TKI) for neovascular age-related macular degeneration. Presented at: Association for Research in Vision and Ophthalmology meeting; April 23-27, 2023; New Orleans.

Disclosures: Moshfeghi reports consulting for Ocular Therapeutix.

Read more about

intravitreal injection
 

Related Content